JAK2 and nasopharyngeal carcinoma: Similarly, both the JAK2 inhibitor and STAT3 inhibitor exhibited a synergistic effect with cisplatin on resistant cells (Figure 4G) which suggests possibilities to develop novel drug combinations with chemotherapy to overcome resistance in NPC.